UK Markets close in 8 hrs 12 mins
  • FTSE 100

    7,758.97
    -25.90 (-0.33%)
     
  • FTSE 250

    19,884.53
    -52.67 (-0.26%)
     
  • AIM

    866.97
    -2.19 (-0.25%)
     
  • GBP/EUR

    1.1389
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.2324
    -0.0030 (-0.2440%)
     
  • BTC-GBP

    18,621.28
    -678.56 (-3.52%)
     
  • CMC Crypto 200

    520.77
    -17.10 (-3.18%)
     
  • S&P 500

    4,017.77
    -52.79 (-1.30%)
     
  • DOW

    33,717.09
    -260.99 (-0.77%)
     
  • CRUDE OIL

    77.23
    -0.67 (-0.86%)
     
  • GOLD FUTURES

    1,926.70
    -12.50 (-0.64%)
     
  • NIKKEI 225

    27,327.11
    -106.29 (-0.39%)
     
  • HANG SENG

    21,839.64
    -230.09 (-1.04%)
     
  • DAX

    15,084.02
    -42.06 (-0.28%)
     
  • CAC 40

    7,075.76
    -6.25 (-0.09%)
     

The Views of 300 Asian Patient Groups on the he Corporate Reputation of Pharma, 2021-2022: Overall Gilead Sciences Ranked 1st, Pfizer Ranked 2nd, and ViiV Healthcare Ranked 3rd

Company Logo
Company Logo

Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Asia Edition - The Views of 300 Asian Patient Groups" report has been added to ResearchAndMarkets.com's offering.

The 'Corporate Reputation of Pharma' survey - the 2021 Asia edition is now in its 4th year, and two years into the Covid-19 pandemic). Between November 2021-February 2022, the survey collected the opinions of 300 Asian patient groups on the performance of the pharmaceutical industry during 2021.

Patient groups possess a unique understanding of the needs of patients, and represent their collated views. As such, patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct, as well as into the evaluation of clinical outcomes. Many patient groups, too, are familiar with the complexities of pharma's business. From their vantage point, therefore, patient groups are both able to assess pharma, and to recommend ways in which companies can improve - all from a patient perspective.

The 300 Asian patient groups responding to the 2021 'Corporate Reputation of Pharma' survey had, collectively, been in communication with nearly 2.7 million Asian patients during 2021. 70% of the respondent Asian patient groups worked or partnered with at least one pharma company that year.

The report provides details on:

  • How the analyst measures pharma's corporate reputation from a patient perspective;

  • The headline results of the 2021 Asia element of the 'Corporate Reputation' survey; including specific results for Australasia and Japan;

  • The companies included in the 2021 Asia analysis; and

  • The profiles of 2021's respondent Asian patient groups.

Company Rankings

  • The top-three pharma companies in Asia in 2021, out of 31 companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups familiar with the company): Gilead Sciences, 1st - Pfizer, 2nd - ViiV Healthcare, 3rd.

  • The top-three pharma companies in Asia in 2021, out of 18 companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups working/partnering with the company): Gilead Sciences, 1st - Pfizer, 2nd - Roche/Chugai, 3rd.

  • The top-three 'big-pharma' companies in Asia in 2021, out of 13 'big-pharma' companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups familiar with the company): Pfizer, 1st - Roche/Chugai, 2nd - Novartis, 3rd.

  • The top-three 'big-pharma' companies in Asia in 2021, out of 13 'big-pharma' companies, ranked for their overall corporate reputation (as assessed by respondent Asian patient groups working/partnering with the company): Pfizer, 1st - Roche/Chugai, 2nd - GSK, 3rd.

Each company is profiled by the following measures:

  • The number of respondent Asian patient groups familiar, and working, with the company, 2021.

  • The profile of the respondent Asian patient groups familiar with the company (the number of patients reached; specialties; and geographic remit), 2021.

  • The types of relationships that the company had with its respondent Asian patient-group partners, 2021.

  • Company performance in Asia at the individual indicators of corporate reputation in 2021-as assessed by respondent Asian patient groups familiar, and working, with the company.

  • Competitors' relationships in 2021 with the company's respondent Asian patient-group partners.

  • Overall rankings in Asia for the company-as assessed by respondent Asian patient groups familiar, and working, with the company, 2021 v. 2020.

  • Company rankings in Asia for each of the indicators-as assessed by respondent Asian patient groups familiar, and working, with the company, 2021 v. 2020.

  • Snapshot view: where the company sits in the corporate tiers in Asia for each of the indicators (in the higher, the middle, or the lower tier)-as assessed by respondent Asian patient groups familiar, and working, with the company, 2021.

  • Overall rankings of the company in Asia, 2016-2021-expressed on the Patient Corporate Reputation Index (PCRI), a measure designed to standardise the analyst's ranking data (preventing results being skewed by the differing numbers of companies included in Asia's historic analyses over the various years). PCRI ranking is from 0 to 1, with 1 being the best (the highest rank)-as assessed by respondent Asian patient groups familiar

Profiles of the 31 companies, 2021

  • AbbVie

  • Amgen

  • Astellas Pharma

  • AstraZeneca

  • Bayer

  • Biogen

  • Boehringer Ingelheim

  • Bristol Myers Squibb

  • CSL Behring

  • Daiichi Sankyo

  • Eisai

  • Eli Lilly

  • Gilead Sciences

  • GSK

  • Ipsen

  • Janssen

  • LEO Pharma

  • Merck KGaA

  • MSD

  • Mylan

  • Novartis

  • Novo Nordisk

  • Otsuka

  • Pfizer

  • Roche (Chugai in Japan)

  • Sandoz

  • Sanofi

  • Sun Pharma

  • Takeda

  • Teva

  • ViiV Healthcare

Key Topics Covered:

  • Executive summary

  • Relationships that Asian patient groups have with pharma, 2021

  • Industry-wide findings in Asia, 2021

  • Rankings of 31 pharma companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups familiar with the companies

  • Rankings of 18 pharma companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups working with the companies

  • Rankings of 13 'big-pharma' companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups familiar with the companies

  • Rankings of 13 'big-pharma' companies in Asia, 2021 v. 2020, as assessed by respondent Asian patient groups working with the companies

  • Profiles of the 31 companies, 2021 (v. 2020)

Appendices

I. Profiles of respondent Asian patient groups, 2021
II. List of respondent Asian patient groups that wished to be attributed, 2021
III. Commentaries and feedback from respondent Asian patient groups on how pharma can improve, 2021-2022
IV. The corporate reputation of pharma, 2021 - Australasia edition [separate supplement]
V. The corporate reputation of pharma, 2021 - Japan edition [separate supplement]

For more information about this report visit https://www.researchandmarkets.com/r/2dqd3m

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900